Introduction
============

Several countries and jurisdictions have decriminalized or legalized the use of medicinal and recreational cannabis, and many others are considering this policy change.[@b1-ahmt-9-137]--[@b6-ahmt-9-137] While cannabis is not legalized for use by children (\<18 years), this has not limited the access of this group. In a large national survey, 15.5% of US youth report using cannabis by Grade 8 and this rises to 44.7% by Grade 12; the daily use of cannabis in Grade 8 students has increased from 0.2% in 1991 to 1.1% in 2015.[@b7-ahmt-9-137],[@b8-ahmt-9-137] With legalization, children will likely have increased access to cannabis and there is a need to understand the effects of its use on health.[@b7-ahmt-9-137],[@b9-ahmt-9-137]

While studies have focused on the mental and neurocognitive effects of cannabis use,[@b10-ahmt-9-137]--[@b13-ahmt-9-137] there is currently limited evidence regarding the effects of its use on the physical health of children, including endocrine and metabolic health.

Importantly, children undergo a pubertal transition that represents a critical period of physical, emotional, and mental development. A key component of this transition is the production of sex steroids, and perturbation of puberty can have lifelong implications on growth, metabolism, and accrual of bone mass.[@b14-ahmt-9-137]--[@b24-ahmt-9-137] Therefore, understanding the implications of cannabis use on physical health in children is critical.

There is evidence from animal studies that cannabis use can lead to pubertal delay, with some evidence suggesting windows of effect on pubertal maturation.[@b25-ahmt-9-137]--[@b27-ahmt-9-137] Specifically, exposure to Δ-9-tetrahydrocannabinol (Δ-9-THC), the primary active compound in cannabis, is associated with delayed sexual maturation and growth spurt in rats.[@b28-ahmt-9-137]

While evidence is limited in humans, a case report noted delayed puberty and low testosterone levels with heavy cannabis smoking.[@b29-ahmt-9-137] When the 16-year-old youth discontinued cannabis, his testosterone levels increased, with advancement in growth velocity and pubertal development.[@b29-ahmt-9-137] Furthermore, lower testosterone levels have been reported in adult males with chronic use of cannabis compared to age-matched controls who did not use cannabis.[@b30-ahmt-9-137] While some of the actions of sex steroids are different in adults compared to children, they are needed in children to go through puberty, which can impact growth, attainment of secondary sexual characteristics, sexual function, bone mass accrual, and psychological well-being.

There is an urgent need to understand the health effects of cannabis use on pubertal timing and tempo in children. This systematic review aims to report on the effects of cannabis use on puberty in humans.

Materials and methods
=====================

This systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO no. CRD42018089397) and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([Table S1](#SD1-ahmt-9-137){ref-type="supplementary-material"}).

Literature searches
-------------------

A Senior Health Sciences Librarian designed the search strategy. Database searches were completed in MEDLINE, Cochrane Central Register of Clinical Trials, Cochrane Database of Systematic Reviews, PsycINFO, Embase, Web of Science, SPORTDiscus, and CINAHL. A gray literature search was also conducted in ProQuest Dissertations and Theses A&I and [Clinicaltrials.gov](http://Clinicaltrials.gov). There were no restrictions on the timing of study conduct or language of study. Literature searches are up to date to February 2018. A sample of the MEDLINE search strategy is reported in [Table 1](#t1-ahmt-9-137){ref-type="table"}. Other search strategies are included in [Tables S2](#SD2-ahmt-9-137){ref-type="supplementary-material"}--[S9](#SD9-ahmt-9-137){ref-type="supplementary-material"}.

Inclusion and exclusion criteria
--------------------------------

Studies including boys and girls who are less than 18 years of age with exposure to recreational or medicinal cannabis were included in this review. The use of cannabis included smoked, ingested, and all other modes of exposure to cannabis products as reported. A minimum of 10 study participants were required for the study to be considered eligible for inclusion.

Eligible study designs included randomized controlled trials, observational studies, prospective and retrospective cohort studies, and case--control studies. Case reports, reviews, and preclinical or animal studies were excluded.

Study selection
---------------

Title, abstract, and full-text screening was independently assessed against the eligibility criteria at each stage by two reviewers. A third reviewer was consulted to resolve persistent disagreements. Reference lists of relevant review articles were hand-searched to identify any additional articles eligible for inclusion in this review.

Data abstraction
----------------

A data abstraction form was developed specifically for this systematic review. Our primary outcome of interest was pubertal timing reported in years or months. The secondary outcomes included pubertal tempo and final height and weight. Tanner staging was the chosen method to assess puberty.[@b31-ahmt-9-137],[@b32-ahmt-9-137] We planned to collect data including the first author's name, year of publication, study design, country, setting, population, sample size, and sex distribution.

Data on cannabis exposure were also to be recorded noting the duration of use, route of administration, dose, frequency, and potential confounders including the use of other illicit drugs, alcohol intake and tobacco smoking. In the case of studies including a control group, data assessing the primary and secondary outcomes were to be abstracted for both groups. For studies including combined data for pediatric and adult populations or if the data included the use of other drugs, the Principal Investigator would be contacted to request data for the pediatric population specifically for cannabis.

Risk of bias and quality assessment
-----------------------------------

Two reviewers planned to independently assess the risk of bias as well as overall quality of the evidence. We chose the Cochrane risk of bias tool for randomized controlled trials[@b33-ahmt-9-137] and Newcastle--Ottawa scale (NOS) to determine the quality of observational studies.[@b34-ahmt-9-137]

If multiple studies had similar study designs, populations, and reported outcomes, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines were chosen to determine the overall quality of evidence.[@b35-ahmt-9-137]

Statistical analysis
--------------------

A meta-analysis would be conducted if two or more studies had similar design, methods, populations, and outcomes. Dichotomous and continuous outcomes were to be reported as ORs and standardized mean differences with 95% CIs, respectively. If possible, a subgroup analysis based on sex will be performed if sufficient data are available.

To evaluate heterogeneity among studies, the inconsistency index (*I*^2^) would be used. The Cochrane Collaboration guidelines would be used to determine the level of heterogeneity across studies.[@b36-ahmt-9-137] An *I*^2^\>75% and a *P*-value of \<0.05 would represent considerable heterogeneity among studies.[@b36-ahmt-9-137] If ten or more studies reported the same outcome, Egger's test to determine the publication bias in addition to interpreting a contour-enhanced funnel plot was chosen.[@b37-ahmt-9-137]

Results
=======

The screening process is reported in [Figure 1](#f1-ahmt-9-137){ref-type="fig"}. The database searches retrieved 706 records, and 53 records were identified through gray literature search. Of the 759 records retrieved, 181 duplicates were removed, leaving 578 unique records for title screening, and from these 96 records were eligible for abstract screening. Abstract screening identified 29 eligible records for full-text screening. All articles (n=29) were excluded following full-text screening as they did not meet the eligibility criteria.

There was one abstract that reported that plasma concentrations of the luteinizing hormone (LH), testosterone, and cortisol were significantly higher in boys using cannabis (n=217), but plasma growth hormone (GH) concentrations were lower during puberty in the cannabis group (n=220).[@b38-ahmt-9-137] Furthermore, the control group was taller and weighed more at the age of 20 years compared to cannabis users.[@b38-ahmt-9-137] However, no full-text publication was identified from this work, and with the limited methodological details available and the number of confounders, it was ultimately excluded.[@b38-ahmt-9-137] We attempted to contact the Principal Investigator of the study, however, were unable to obtain additional data.

Due to the limited evidence base, we searched records for any eligible records with less than ten subjects, including case studies or reports. However, only the one case report was identified.[@b29-ahmt-9-137]

Discussion
==========

As the use of cannabis rises,[@b7-ahmt-9-137],[@b8-ahmt-9-137] the effects of its use on children's health are still widely unknown. Based on animal data and very limited evidence from human studies, the exposure of children to cannabis may affect pubertal development and growth spurt. In addition, pubertal hormones are important contributors to bone mass accrual and the effect of cannabis use on bone health is important to understand.[@b15-ahmt-9-137] This systematic review evaluated the existing evidence on the effect of cannabis exposure on pubertal outcomes in children. Following a comprehensive literature search and screening process, no existing articles provided answers to the question of cannabis effects on puberty.

Cannabis consists of several compounds called cannabinoids, and Δ-9-THC is its main psychoactive component.[@b39-ahmt-9-137] With limited clinical data, animal studies are one of the few models that may provide insights on the potential impact of cannabis use on pediatric endocrine and metabolic health.[@b40-ahmt-9-137] The administration of Δ-9-THC to animals leads to delayed sexual maturation and impaired gonadal function.[@b26-ahmt-9-137] For example, female rats receiving Δ-9-THC had fewer ova on the first day of estrus when compared with controls.[@b25-ahmt-9-137],[@b41-ahmt-9-137] Furthermore, the female rats receiving Δ-9-THC had lower levels of LH during proestrus, estrus, and diestrus and lower follicle-stimulating hormone (FSH) at diestrus.[@b25-ahmt-9-137] In male rats, chronic administration of Δ-9-THC led to significant reduction in the pubertal growth spurt when compared with controls with lower endogenous testosterone, dihydrotestosterone (DHT), LH, and FSH levels in Δ-9-THC-treated rats, which likely explain the noted phenotype.[@b28-ahmt-9-137] As LH and FSH stimulate gonadal production of testosterone and estradiol, gametogenesis, and ovulation, animal data suggest that cannabis affects the hypothalamic--pituitary--gonadal axis.[@b42-ahmt-9-137]--[@b44-ahmt-9-137]

The preclinical reports on important effects of chronic exposure to Δ-9-THC on puberty may be relevant to inform human studies. Importantly, the daily doses administered to rodents in these studies varied from 4 mg/kg[@b28-ahmt-9-137] to as low as 0.001 mg/k[@b25-ahmt-9-137],[@b41-ahmt-9-137] which are comparable to the doses of Δ-9-THC exposure in humans that range from 0.1 to 3.9 mg/kg.[@b45-ahmt-9-137] With the progressive increase in daily use of cannabis in children,[@b7-ahmt-9-137] the physical health effects of exposure, as well as dosing and frequency on pubertal development, are increasingly important to understand and need to be considered in future studies.

While there were no eligible studies for inclusion in this systematic review, we identified one case report and one abstract relevant to our topic.[@b29-ahmt-9-137],[@b38-ahmt-9-137] Both records supported the observations from preclinical studies that cannabis use may impact pubertal development. The two reports included only male subjects and both observed delayed puberty and reduced growth spurt in cannabis users.[@b29-ahmt-9-137],[@b38-ahmt-9-137] However, while the case report observed lower testosterone levels with cannabis use,[@b29-ahmt-9-137] the abstract we identified reported higher concentrations of LH, testosterone, and cortisol, yet lower GH concentrations in cannabis users compared to controls.[@b38-ahmt-9-137] This abstract suggested that cannabis use may accelerate puberty and suppress growth. There were several descriptors that were not reported in the abstract, and this precluded the confirmation of the conclusion of the abstract. This limited evidence base needs to be interpreted with caution and does not fully clarify the potential impact of cannabis on puberty.

In the general population, delayed pubertal development has been associated with future adverse health outcomes in adults. Studies in non-cannabis users have found that delayed puberty in men may lead to reduced bone mineral density compared to those with normal puberty.[@b15-ahmt-9-137] In women, delayed menarche is a potential risk factor for low peak bone mass as well as irregular menstrual cycles and infertility.[@b46-ahmt-9-137],[@b47-ahmt-9-137] Therefore, understanding the effect of cannabis exposure on pubertal development in children is important to monitor those who may be at risk of future health concerns.

There is also some evidence linking infertility with cannabis use. Studies in adults have suggested that women were twice as likely to experience infertility if they had smoked cannabis within a year of attempted conception, compared to women who had never used cannabis.[@b48-ahmt-9-137],[@b49-ahmt-9-137]

Male rat studies demonstrated a significant decrease in the progressive motility of sperms, sperm counts, and seminiferous tubules' development with cannabis use compared with controls.[@b50-ahmt-9-137] A study on human sperms found that cannabis exposure resulted in a sperm quality and concentration.[@b51-ahmt-9-137]

Adequately powered prospective cohort studies are needed to address the impact of cannabis use in children and adolescents on pubertal timing, tempo, final height, sexual maturation, sexual function, and future fertility.

The main strengths of this systematic review include the pursuit of an extensive search strategy and its rigorous methodology. There were no restrictions in terms of language or date of publication of papers.

The main limitation of this review is the lack of studies evaluating the use of cannabis in humans and its effect on pubertal outcomes.

Conclusion
==========

There is an important gap in the existing evidence base linking cannabis and pubertal outcomes in children. Preclinical studies have suggested potential negative effects of cannabis use on sexual maturation, gonadotrophins, and gonadal function. However, there are currently no existing longitudinal studies to evaluate these and other physical health effects in children. Despite the increased cannabis use in children and adolescents,[@b7-ahmt-9-137] the main focus of research has been on the psychiatric outcomes and neurocognitive deficits resulting from its use, while the impact on physical health has received less attention.[@b10-ahmt-9-137] Pediatricians and other health care providers require high-quality information to council their young patients regarding the potential physical health effects of cannabis, as this may influence the decision of children and youth to use cannabis. In addition, this information may also clarify the need for policy makers to support the development of screening and treatment strategies for those who decide to use cannabis, if potential negative health impacts are identified to reduce potential harms on physical health and development.

As puberty is a critical window of physical growth and development, the fact that there are no studies addressing cannabis effects on these aspects of health makes this a critical area of future investigation in this new era of increased access.

Supplementary materials
=======================

###### 

Preferred reporting items for systematic review and meta-analysis checklist

  Section/topic                        \#   Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  **Title**                                                                                                                                                                                                                                                                                                                                               
  Title                                1    Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **Abstract**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2    Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   3
  **Introduction**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                4--5
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to PICOS.                                                                                                                                                                                                                           5
  **Methods**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number.                                                                                                                                   5 (registration number)
  Eligibility criteria                 6    Specify study characteristics (eg, PICOS and length of follow-up) and report characteristics (e.g., years considered, language, and publication status) used as criteria for eligibility, giving rationale.                                                                                                   5--6
  Information sources                  7    Describe all information sources (e.g., databases with dates of coverage and contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                 5--6
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 18 ([Table 1](#t1-ahmt-9-137){ref-type="table"})
  Study selection                      9    State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                       6
  Data collection process              10   Describe the method of data extraction from reports (eg, piloted forms, independently, and in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                              6
  Data items                           11   List and define all variables for which data were sought (eg, PICOS and funding sources) and any assumptions and simplifications made.                                                                                                                                                                        6
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        6--7
  Summary measures                     13   State the principal summary measures (eg, risk ratio and difference in means).                                                                                                                                                                                                                                7
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis.                                                                                                                                                       7
  **Section/topic**                    \#   **Checklist item**                                                                                                                                                                                                                                                                                            **Reported on page \#**
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias and selective reporting within studies).                                                                                                                                                                 7
  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses and meta-regression), if done, indicating which were pre-specified.                                                                                                                                                             7
  **Results**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               7, 18 ([Figure 1](#f1-ahmt-9-137){ref-type="fig"})
  Study characteristics                18   For each study, present characteristics for which data were extracted (eg, study size, PICOS, and follow-up period) and provide the citations.                                                                                                                                                                7--8
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     N/A
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and CIs, ideally with a forest plot.                                                                                                                   7--8
  Synthesis of results                 21   Present results of each meta-analysis done, including CIs and measures of consistency.                                                                                                                                                                                                                        N/A
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               N/A
  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses and meta-regression \[see Item 16\]).                                                                                                                                                                                      N/A
  **Discussion**                                                                                                                                                                                                                                                                                                                                          
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, health care providers, users, and policy makers).                                                                                                                           8
  Limitations                          25   Discuss limitations at study and outcome level (eg, risk of bias) and at review-level (eg, incomplete retrieval of identified research and reporting bias).                                                                                                                                                   10
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence and implications for future research.                                                                                                                                                                                        10--11
  **Funding**                                                                                                                                                                                                                                                                                                                                             
  Funding                              27   Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.                                                                                                                                                                      12

**Note:** Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7):e1000097.[@b52-ahmt-9-137]

**Abbreviation:** PICOS, participants, interventions, comparisons, outcomes, and study design.

###### 

Cochrane central register of controlled trials search strategy

  \#   Searches
  ---- --------------------------------------------
  1    Cannabis/
  2    exp Cannabinoids/
  3    marijuana.mp.
  4    cannabi\*.mp.
  5    marihuana.mp.
  6    ganja\*.mp.
  7    bhang\*.mp.
  8    or/1--7
  9    exp Puberty/
  10   pubert\*.mp.
  11   sex\* precoci\*.mp.
  12   puberty, delayed/or puberty, precocious/
  13   Sexual Development/
  14   Sexual Maturation/
  15   (sexual adj2 (development or matur\*)).mp.
  16   or/9--15
  17   8 and 16
  18   remove duplicates from 17
  19   18 not (animals/not (humans/and animals/))

###### 

Cochrane database of systematic reviews search strategy

  \#   Searches
  ---- ----------------------------------------------
  1    \[Cannabis/\]
  2    \[exp Cannabinoids/\]
  3    marijuana.mp.
  4    cannabi\*.mp.
  5    marihuana.mp.
  6    ganja\*.mp.
  7    bhang\*.mp.
  8    or/1--7
  9    \[exp Puberty/\]
  10   pubert\*.mp.
  11   sex\* precoci\*.mp.
  12   \[puberty, delayed/or puberty, precocious/\]
  13   \[Sexual Development/\]
  14   \[Sexual Maturation/\]
  15   (sexual adj2 (development or matur\*)).mp.
  16   or/9--15
  17   8 and 16
  18   remove duplicates from 17
  19   118 not (animals/not (humans/and animals/))

###### 

PsycINFO search strategy

  \#   Searches
  ---- --------------------------------------------
  1    Cannabis/
  2    exp Cannabinoids/
  3    marijuana.mp.
  4    cannabi\*.mp.
  5    marihuana.mp.
  6    ganja\*.mp.
  7    bhang\*.mp.
  8    or/1--7
  9    Puberty/
  10   pubert\*.mp.
  11   sex\* precoci\*.mp.
  12   menarche/
  13   menarche.mp.
  14   adrenarche.mp.
  15   Sexual Development/
  16   (sexual adj2 (development or matur\*)).mp.
  17   or/9--16
  18   8 and 17
  19   remove duplicates from 18
  20   19 not (animals/not (humans/and animals/))

###### 

Embase search strategy

  \#   Searches
  ---- ----------------------------------------------------------------------------
  1    cannabis/
  2    cannabinoid/or cannabichromene/or cannabidiol/or cannabinol/or dronabinol/
  3    cannabi\*.mp.
  4    marihuana.mp.
  5    marijuana.mp.
  6    ganja\*.mp.
  7    bhang\*.mp.
  8    dronabinol\*.mp.
  9    or/1--8
  10   exp puberty/
  11   pubert\*.mp.
  12   menarche.mp.
  13   adrenarche.mp.
  14   delayed puberty/
  15   precocious puberty/
  16   sex\* precoci\*.mp.
  17   pubarche.mp.
  18   thelarche.mp.
  19   sexual development/
  20   sexual maturation/
  21   (sexual adj2 (development or matur\*)).mp.
  22   or/10--21
  23   9 and 22
  24   remove duplicates from 23
  25   24 not (animals/not (humans/and animals/))

###### 

Web of science search strategy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  (marijuana or cannabi\* or marihuana or ganja\* or bhang\*) AND TOPIC: (pubert\* or menarche or adrenarche or sexual development or sexual matur\* or sex\* preocoicious\*) Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

SPORTDiscus search strategy

  \#    Searches
  ----- -------------------------------------------
  S1    cannabi\*
  S2    DE "CANNABIS"
  S3    marijuana or marihuana or ghanja or bhang
  S4    S1 OR S2 OR S3
  S5    pubert\*
  S6    DE "PUBERTY" OR DE "MENARCHE"
  S7    menarche or adrenarche Search modes -
  S8    sexual maturation
  S9    sex\* precoci\*
  S10   sexual N2 (development or matur\*)
  S11   S5 OR S6 OR S7 OR S8 OR S9 OR S10
  S12   S4 AND S11

###### 

CINAHL search strategy

  \#    Searches
  ----- ---------------------------------------------------------------------
  S1    (MH "Cannabis")
  S2    "marijuana" or "cannabi\*" or "marihuana" or "ganja\*" or "bhang\*"
  S3    S1 OR S2
  S4    (MH "Puberty+")
  S5    "pubert\*" or "menarche" or "adrenarche"
  S6    (MH "Puberty, Precocious") OR (MH "Puberty, Delayed")
  S7    "sex\* precocious\*"
  S8    sexual N2 (development or matur\*)
  S9    S4 OR S5 OR S6 OR S7 OR S8
  S10   S3 AND S9

###### 

ProQuest dissertations and theses A&I search strategy

  Searches
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  All ((marijuana OR cannabi\* OR marihuana OR ganja\* OR bhang\*)) AND all ((pubert\* or menarche or adrenarche or sexual development or sexual matur\* or sex\* preocoicious\*))
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###### 

MEDLINE search strategy

  \#   Searches
  ---- --------------------------------------------
  1    Cannabis/
  2    exp Cannabinoids/
  3    marijuana.mp.
  4    cannabi\*.mp.
  5    marihuana.mp.
  6    ganja\*.mp.
  7    bhang\*.mp.
  8    or/1--7
  9    exp Puberty/
  10   pubert\*.mp.
  11   sex\* precoci\*.mp.
  12   puberty, delayed/or puberty, precocious/
  13   Sexual Development/
  14   Sexual Maturation/
  15   (sexual adj2 (development or matur\*)).mp.
  16   or/9--15
  17   8 and 16
  18   remove duplicates from 17
  19   18 not (animals/not (humans/and animals/))
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